Breaking News Instant updates and real-time market news.

VRX

Valeant

$15.44

-0.35 (-2.22%)

07:05
04/09/18
04/09
07:05
04/09/18
07:05

Ortho Dermatologics: JAAD publishes results of Phase trials of DUOBRII

Ortho Dermatologics, a division of Valeant Pharmaceuticals, announced that the Journal of the American Academy of Dermatology published for the first time positive results from two Phase 3, multicenter, randomized, double-blind clinical trials (Studies 1 and 2) to assess the safety and efficacy of DUOBRIITM lotion in the treatment of plaque psoriasis.2 Studies 1 and 2, which enrolled a total of 418 patients, showed DUOBRII was consistently more effective than vehicle in achieving treatment success (defined as those with at least a two-grade improvement from baseline in an Investigator Global Assessment score, and 'clear' or 'almost clear' skin), demonstrating statistically significant superiority by week four (in Study 1) and week two (in Study 2). At week eight, 35.8% (Study 1) and 45.3% (Study 2) had achieved the primary efficacy outcome, compared to 7% and 12.5% on vehicle. The majority of patients maintained treatment success over the four-week post treatment period. DUOBRII was also superior in reducing psoriasis signs and symptoms and body surface area affected compared to vehicle. In addition, DUOBRII showed significant reductions in the severity of the clinical signs of psoriasis. The most common treatment-related adverse events were contact dermatitis (6.3%), application site pain (2.6%) and pruritus (2.2%).

  • 08

    May

  • 13

    May

  • 18

    Jun

  • 27

    Aug

VRX Valeant
$15.44

-0.35 (-2.22%)

03/21/18
DBAB
03/21/18
NO CHANGE
Target $20
DBAB
Buy
Deutsche Bank continues to like risk/reward for Valeant shares
Valeant Pharmaceuticals could get more credit for its dermatology pipeline over time as it discloses more details on assets, secures approvals, and executes on launches, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He notes that one key difference between Valeant's longer-term outlook and his model is sales potential for the dermatology business. Management believes it can double sales from 2018-2022 to greater than $1B while Gilbert's estimates are much lower at $600M, likely due to lower pipeline contribution. He believes success in dermatology would represent "significant upside" to his current price target of $20. The analyst continues to like the risk/reward for the stock and maintains a Buy rating on Valeant.
04/06/18
MZHO
04/06/18
UPGRADE
Target $15
MZHO
Neutral
Valeant upgraded to Neutral from Underperform at Mizuho
Mizuho analyst Irina Koffler upgraded Valeant to Neutral and raised its price target to $15 from $10. Koffler sees a lack of near-term sell catalysts and views 2018 guidance as achievable.
04/06/18
MZHO
04/06/18
UPGRADE
Target $15
MZHO
Neutral
Mizuho upgrades Valeant to Neutral on lack of negative catalysts
Mizuho analyst Irina Koffler upgraded Valeant Pharmaceuticals to Neutral from Underperform and raised her price target for the shares to $15 from $10. The drugmaker closed yesterday at $15.79. The analyst, while remaining concerned about Valeant's return to revenue growth, sees no near-term "sell catalysts." Further, she views the company's 2018 guidance as achievable.
04/06/18
04/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Valeant (VRX) upgraded to Neutral from Underperform at Mizuho with analyst Irina Koffler saying while she remains concerned about Valeant's return to revenue growth, sees no near-term "sell catalysts." 2. Patterson Companies (PDCO) upgraded to Buy from Hold at Craig-Hallum with analyst Kevin Ellich saying that his sum-of-parts analysis suggests the company could unlock value by splitting its dental and animal health businesses. 3. Prologis (PLD) and AvalonBay (AVB) were upgraded to Buy from Neutral at Citi. 4. Universal Display (OLED) upgraded to Outperform from Perform at Oppenheimer with analyst Andrew Uerkwitz saying with the shares down 41% year-to-date, the stock is oversold and the risks are fully priced in. 5. Halyard Health (HYH) upgraded to Overweight from Sector Weight at KeyBanc with analyst Matthew Mishan saying he sees the company's earnings growth accelerating and valuation re-rating following the sale of its Surgical & Infection Prevention unit. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

05:50
04/25/18
04/25
05:50
04/25/18
05:50
General news
FX Action: USD-JPY corrected to a 108.98 low »

FX Action: USD-JPY…

CHKP

Check Point

$102.95

0.17 (0.17%)

05:38
04/25/18
04/25
05:38
04/25/18
05:38
Earnings
Check Point reports Q1 EPS $1.30, consensus $1.28 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

DISCA

Discovery

$23.94

0.17 (0.72%)

05:36
04/25/18
04/25
05:36
04/25/18
05:36
Hot Stocks
Discovery enters partnership with Digital Element »

Digital Element announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

SOGO

Sogou

$8.55

0.15 (1.79%)

05:35
04/25/18
04/25
05:35
04/25/18
05:35
Earnings
Breaking Earnings news story on Sogou »

Sogou sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SOGO

Sogou

$8.55

0.15 (1.79%)

05:34
04/25/18
04/25
05:34
04/25/18
05:34
Earnings
Sogou reports Q1 EPS 5c, consensus 3c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CYOU

Changyou.com

$28.79

-0.9 (-3.03%)

05:32
04/25/18
04/25
05:32
04/25/18
05:32
Earnings
Changyou.com sees Q2 EPS 38c-47c, consensus 53c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CYOU

Changyou.com

$28.79

-0.9 (-3.03%)

05:30
04/25/18
04/25
05:30
04/25/18
05:30
Earnings
Changyou.com reports Q1 adj. EPS (30c), may not compare to consensus 53c »

Reports Q1 revenue $137M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SOHU

Sohu.com

$30.26

-0.65 (-2.10%)

05:29
04/25/18
04/25
05:29
04/25/18
05:29
Earnings
Sohu.com sees Q2 EPS ($1.65)-($1.40), consensus ($1.32) »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SOHU

Sohu.com

$30.26

-0.65 (-2.10%)

05:28
04/25/18
04/25
05:28
04/25/18
05:28
Earnings
Breaking Earnings news story on Sohu.com »

Sohu.com reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SOHU

Sohu.com

$30.26

-0.65 (-2.10%)

05:26
04/25/18
04/25
05:26
04/25/18
05:26
Earnings
Sohu.com reports Q1 EPS ($2.39), consensus ($1.56) »

Reports Q1 revenue $455M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

FOSL

Fossil

$14.21

-0.165 (-1.15%)

05:25
04/25/18
04/25
05:25
04/25/18
05:25
Hot Stocks
Fossil signs global license partnership with PUMA for watches, smartwatches »

Fossil Group and PUMA SE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$77.00

-0.595 (-0.77%)

05:23
04/25/18
04/25
05:23
04/25/18
05:23
Hot Stocks
Novartis announces launch of FocalView app »

Novartis announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 21

    May

  • 05

    Jun

EEFT

Euronet

$75.32

-1.04 (-1.36%)

05:22
04/25/18
04/25
05:22
04/25/18
05:22
Earnings
Breaking Earnings news story on Euronet »

Euronet sees Q2 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

EEFT

Euronet

$75.32

-1.04 (-1.36%)

05:21
04/25/18
04/25
05:21
04/25/18
05:21
Earnings
Euronet reports Q1 adj. EPS 73c, consensus 73c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ILMN

Illumina

$238.65

-7.19 (-2.92%)

05:02
04/25/18
04/25
05:02
04/25/18
05:02
Recommendations
Illumina analyst commentary  »

Illumina target upped to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 24

    May

  • 12

    Jun

PPG

PPG

$105.74

-3.12 (-2.87%)

04:56
04/25/18
04/25
04:56
04/25/18
04:56
Upgrade
PPG rating change  »

PPG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$151.02

-2.07 (-1.35%)

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Accenture to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

AKAM

Akamai

$70.95

-0.73 (-1.02%)

, MRK

Merck

$60.08

-0.16 (-0.27%)

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Boardroom Resources to hold a summit »

2018 Boardroom Summit…

AKAM

Akamai

$70.95

-0.73 (-1.02%)

MRK

Merck

$60.08

-0.16 (-0.27%)

JNJ

Johnson & Johnson

$126.18

-0.65 (-0.51%)

LPLA

LPL Financial

$61.04

-0.5 (-0.81%)

GHC

Global Consumer Acquisition Corporation

$611.35

-4.65 (-0.75%)

FUN

Cedar Fair

$63.63

-0.44 (-0.69%)

DECK

Deckers Brands

$90.83

1.13 (1.26%)

CPB

Campbell Soup

$41.08

0.25 (0.61%)

BURBY

Burberry

AWK

American Water

$84.79

0.5 (0.59%)

BLK

BlackRock

$514.01

-5.79 (-1.11%)

STT

State Street

$101.07

-1.28 (-1.25%)

EA

Electronic Arts

$118.56

-0.99 (-0.83%)

HSY

Hershey

$92.81

-0.33 (-0.35%)

EQR

Equity Residential

$60.62

0.21 (0.35%)

APOG

Apogee Enterprises

$41.55

-1.11 (-2.60%)

VMC

Vulcan Materials

$111.32

-2.53 (-2.22%)

WEN

Wendy's

$16.84

-0.385 (-2.24%)

TWX

Time Warner

$96.02

-0.32 (-0.33%)

AMGN

Amgen

$171.91

-2.75 (-1.57%)

AGN

Allergan

$156.91

-2.98 (-1.86%)

CSCO

Cisco

$43.74

-0.49 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 15

    May

  • 17

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 28

    May

  • 30

    May

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 12

    Jun

  • 14

    Jun

  • 23

    Oct

ANF

Abercrombie & Fitch

$27.03

0.265 (0.99%)

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Abercrombie & Fitch to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 12

    Jun

NVS

Novartis

$77.00

-0.595 (-0.77%)

, GSK

GlaxoSmithKline

$40.63

0.29 (0.72%)

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Drug Information Association to hold a forum »

Biostatistics Industry…

NVS

Novartis

$77.00

-0.595 (-0.77%)

GSK

GlaxoSmithKline

$40.63

0.29 (0.72%)

LLY

Eli Lilly

$80.09

-0.16 (-0.20%)

AZN

AstraZeneca

$35.13

-0.4 (-1.13%)

MRK

Merck

$60.08

-0.16 (-0.27%)

AMGN

Amgen

$171.91

-2.75 (-1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 27

    Apr

  • 30

    Apr

  • 01

    May

  • 07

    May

  • 08

    May

  • 15

    May

  • 17

    May

  • 18

    May

  • 21

    May

  • 22

    May

  • 28

    May

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 23

    Oct

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
UBS basic materials analyst to hold an analyst/industry conference call »

Basic Materials Analyst…

SBPH

Spring Bank Pharmaceuticals

$14.50

0.18 (1.26%)

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Spring Bank Pharmaceuticals management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 25

    May

IOVA

Iovance Biotherapeutics

$14.40

-0.1 (-0.69%)

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Iovance Biotherapeutics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 21

    May

04:55
04/25/18
04/25
04:55
04/25/18
04:55
General news
Breaking General news story  »

Week of 4/20 MBA Mortgage…

CHPE

Chaparral Energy

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Chaparral Energy management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.